Eli Lilly and Company

Sr. Scientist Peptides - Person in Plant

Amissville, Virginia, United States

Eli Lilly and Company Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates should possess a Ph.D. in a relevant scientific discipline, such as Biochemistry, Molecular Biology, or a related field, and have at least 8 years of experience in peptide synthesis and characterization. Strong knowledge of cGMPs, applicable global regulatory manufacturing guidance, and Lilly’s systems is required, along with experience in process monitoring, response to issues, and improvements.

Responsibilities

The Sr. Scientist Peptides – Person in Plant will develop and sustain process knowledge to ensure the reliable supply and commercialization of medicines at the Contract Manufacturer (CM), directly and indirectly interacting with CM personnel. They will participate in technical transfer, process validation, and process data monitoring, adhering to the Lilly Red Book expectations. The role involves process monitoring, responding to issues, and implementing improvements, working cross-functionally within Lilly and with CM resources to deliver technical objectives and build relationships with development and central technical organizations.

Skills

Manufacturing principles
cGMPs
Global regulatory guidance
Cross-functional collaboration
Communication skills
Unit operation control
Process development
Process validation
Data monitoring
Operational control

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Key Metrics

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI